GoAI
Get started
Mediwelcome Healthcare Management & Technology Inc. logo

Mediwelcome Healthcare Management & Technology Inc.

2159.HK

HKSEHealthcareMedical - Healthcare Information Services

Open in GoAI

Latest quote

HK$1.80

+HK$0.05 · +2.86%

Aug 24, 3:47 PM HKT

2159.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

As an investment holding entity, Mediwelcome Healthcare Management & Technology Inc. delivers comprehensive marketing solutions for the healthcare sector within the People's Republic of China. Its service portfolio encompasses medical conference organization, patient education and screening programs, along with strategic marketing and advisory support. Additionally, the company provides Contract Research Organization (CRO) services, specifically focusing on patient recruitment and clinical data gathering. Furthermore, Mediwelcome manages a mobile application that facilitates internet hospital functionalities, including virtual follow-up consultations for physicians' current patients and electronic prescription services. Its diverse client base includes pharmaceutical firms, medical associations, and various foundations. Established in 2000, Mediwelcome Healthcare Management & Technology Inc. maintains its headquarters in Beijing, China.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
Headquarters
CN
CEO
Liang Wang
Listed since
Jan 19, 2021
Employees
150

Market position

Day range

Current HK$1.80

52-week range

Current HK$1.80

Open
HK$1.76
Previous close
HK$1.75
Volume
576.8K
3.68× average
Average volume
156.91K
Average daily volume
Market cap
488.6M HKD
Beta
-0.26
Market reference 1
50-day average
HK$1.6395
+9.79% above average
200-day average
HK$1.496
+20.32% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
194.78M CNY
P/E (TTM)
11.16×
P/B (TTM)
2.71×
P/S (TTM)
0.74×
EV / EBITDA
69.34×
Earnings yield
4.17%
Free cash flow yield
1.03%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
24.92%
Operating margin
4.41%
Net margin
5.94%
Return on equity
8.97%
Return on assets
5.24%
Return on invested capital
1.14%

Financial health

Debt / equity
0.5×
Current ratio
1.89×
Altman Z-score
2.39
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends25%5%-15%-35%Gross margin, FY2021: 13.21%Gross margin, FY2022: 10.07%Gross margin, FY2023: 9.02%Gross margin, FY2024: 15.86%Gross margin, FY2025: 20.24%Operating margin, FY2021: 0.94%Operating margin, FY2022: -30.01%Operating margin, FY2023: -24.72%Operating margin, FY2024: -11.26%Operating margin, FY2025: 0.39%Net margin, FY2021: 0.66%Net margin, FY2022: -27.58%Net margin, FY2023: -28.40%Net margin, FY2024: -14.07%Net margin, FY2025: 2.13%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 13.21%. Gross margin FY2022 10.07%. Gross margin FY2023 9.02%. Gross margin FY2024 15.86%. Gross margin FY2025 20.24%. Operating margin FY2021 0.94%. Operating margin FY2022 -30.01%. Operating margin FY2023 -24.72%. Operating margin FY2024 -11.26%. Operating margin FY2025 0.39%. Net margin FY2021 0.66%. Net margin FY2022 -27.58%. Net margin FY2023 -28.40%. Net margin FY2024 -14.07%. Net margin FY2025 2.13%.

Income trends

Revenue

468.02M CNY+45.55%

Operating income

1.82M CNY+38.03M CNY

Net income

9.99M CNY+55.23M CNY
Income trends across reported periods788.9M CNY466.74M CNY144.58M CNY−177.57M CNYRevenue, FY2021: 708.36M CNYRevenue, FY2022: 323.37M CNYRevenue, FY2023: 331.31M CNYRevenue, FY2024: 321.56M CNYRevenue, FY2025: 468.02M CNYOperating income, FY2021: 6.67M CNYOperating income, FY2022: −97.04M CNYOperating income, FY2023: −81.92M CNYOperating income, FY2024: −36.21M CNYOperating income, FY2025: 1.82M CNYNet income, FY2021: 4.65M CNYNet income, FY2022: −89.2M CNYNet income, FY2023: −94.1M CNYNet income, FY2024: −45.25M CNYNet income, FY2025: 9.99M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 708.36M CNY. Revenue FY2022 323.37M CNY. Revenue FY2023 331.31M CNY. Revenue FY2024 321.56M CNY. Revenue FY2025 468.02M CNY. Operating income FY2021 6.67M CNY. Operating income FY2022 −97.04M CNY. Operating income FY2023 −81.92M CNY. Operating income FY2024 −36.21M CNY. Operating income FY2025 1.82M CNY. Net income FY2021 4.65M CNY. Net income FY2022 −89.2M CNY. Net income FY2023 −94.1M CNY. Net income FY2024 −45.25M CNY. Net income FY2025 9.99M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue468.02M CNY321.56M CNY331.31M CNY323.37M CNY708.36M CNY
Cost of goods sold373.31M CNY270.55M CNY301.41M CNY290.82M CNY614.76M CNY
Gross profit94.71M CNY51M CNY29.9M CNY32.55M CNY93.6M CNY
Research and development27.94M CNY18.68M CNY32.69M CNY50.61M CNY18.7M CNY
Selling, general, and administrative63.7M CNY60.59M CNY73.35M CNY75.56M CNY84.75M CNY
Operating expenses92.89M CNY87.21M CNY111.81M CNY123.54M CNY95.55M CNY
Interest income235.74K CNY264K CNY415K CNY623K CNY792K CNY
Interest expense1.4M CNY1.09M CNY1.3M CNY1.25M CNY1.26M CNY
Depreciation and amortization990K CNY2.6M CNY20.55M CNY20.71M CNY4.65M CNY
Operating income1.82M CNY−36.21M CNY−81.92M CNY−97.04M CNY6.67M CNY
Net income9.99M CNY−45.25M CNY−94.1M CNY−89.2M CNY4.65M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.12

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.17-0.01-0.19-0.38Q2 '21Q4 '21Q2 '22Q4 '22Q2 '23Q2 '24Q2 '24Q2 '25
Q2 2021, reported Jun 30, 2021: actual -0.108, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual 0.132, estimate —, surprise —, Comparison unavailable. Q2 2022, reported Jun 30, 2022: actual -0.291, estimate —, surprise —, Comparison unavailable. Q4 2022, reported Dec 31, 2022: actual -0.263, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Jun 30, 2023: actual -0.201, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 26, 2024: actual -0.338, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 30, 2024: actual -0.125, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Jun 26, 2025: actual -0.12, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates475.27M359.65M244.03M128.41MQ2 '21Q4 '21Q2 '22Q4 '22Q2 '23Q2 '24Q2 '24Q2 '25
Q2 2021, reported Jun 30, 2021: actual 407.97M HKD, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual 451.25M HKD, estimate —, surprise —, Comparison unavailable. Q2 2022, reported Jun 30, 2022: actual 201.89M HKD, estimate —, surprise —, Comparison unavailable. Q4 2022, reported Dec 31, 2022: actual 171.88M HKD, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Jun 30, 2023: actual 158.89M HKD, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 26, 2024: actual 204.08M HKD, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 30, 2024: actual 151.07M HKD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Jun 26, 2025: actual 180.89M HKD, estimate —, surprise —, Comparison unavailable.

2159.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

Continue in GoAI

Research 2159.HK

research.disclaimer